ImmuNovX Biotech
ImmuNovX Biotech
Categories
Biotechnology
About
ImmuNovX Biotech is an early-stage company whose mission is to develop the groundbreaking technology we call LR3N-CS, a platform that allows rapid, large-scale treatment of DNA pathogens to generate a novel class of vaccines.
The LR3N-CS platform technology chemically binds the DNA of treated pathogens via a cell-free manufacturing process, resulting in live-attenuated, replication-defective DNA pathogens. The system significantly reduces the time required to develop, manufacture, and deploy DNA pathogen vaccines, at a fraction of the cost of currently-available processes --enabling a novel class of DNA vaccines.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.